SCYNEXIS, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
SCYNEXIS, Inc. (SCYX) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $1.74 million as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2023-05-10
- 2023-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.74M.
- 2022-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.22M.
- 2022-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.44M.
- 2022-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.67M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net as first filed |
|---|---|---|
| 2023-03-31 | $1.74M 10-Q · filed 2023-05-10 | |
| 2022-09-30 | $2.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.44M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $2.67M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.99M 10-K · filed 2023-03-31 | $2.44M 10-K · filed 2022-03-29 |
| 2021-09-30 | $2.61M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $2.81M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |